Credit: Getty Images. Shionogi has announced positive results from the phase 3 APEKS-NP trial of cefiderocol (S-649266) for the treatment of nosocomial pneumonia. Shionogi has announced positive ...

Patients were randomized to receive cefiderocol intravenously (IV) every 8 hours (n=145) or meropenem IV every 8 hours (n=146) for a period of 7-14 days, in addition to linezolid (to cover methicillin ...

In a study, IV fosfomycin appeared less effective than IV ceftriaxone or meropenem for bacteremic UTI caused by multidrug-resistant E. coli, but the drug may be considered for selected patients with ...

Zerbaxa is noninferior to meropenem for the treatment of adult patients with ventilated nosocomial pneumonia, or VNP, according to phase 3 data from the ASPECT-NP trial presented at the European ...